Melanoma is the most dangerous form of skin cancer. It is the fifth most common cancer overall, behind breast, lung, prostate, and colorectal. It can rapidly grow and spread to any part of the body. Melanoma is most often caused by exposure to ultraviolet (UV) rays. Overexposure to UV rays — whether from the sun, sun lamps, or tanning beds — damages the DNA of genes that control skin-cell growth. These damaged genes (mutations) instruct cells to multiply rapidly and form malignant tumors. Melanoma often looks like a mole. It is usually black or brown, but it can also be skin-colored, purple, blue, red, pink, or white.
The melanoma sector is advancing, particularly in melanoma drugs and diagnostics markets. As the melanoma market expands, early detection and effective treatment options become more important than ever, impacting patient outcomes and survival rates.
The global market for melanoma therapeutics is estimated to increase from $7.4 billion in 2023 to reach $12.1 billion by 2028, growing at a compound annual growth rate (CAGR) of 10.2% from 2023 through 2028 during the forecast period. Melanoma therapeutics featuring cutting-edge technology that are user-friendly and offer precise treatment options are witnessing a surge in popularity.